ReNerve secures $517k R&D tax refund to support nerve repair commercialisation
ReNerve Limited (ASX: RNV) has received a $517,133 R&D Tax Incentive Refund from the Australian Tax Office, relating to eligible research and development activities conducted during the 2024-25 income year. The non-dilutive funding will strengthen the company’s cash position and support ongoing product development and commercialisation initiatives.
What is the R&D Tax Incentive Scheme?
The Australian Government’s R&D Tax Incentive Scheme provides tax offsets to encourage companies to engage in innovative research and development activities. For early-stage biotechnology companies like ReNerve, this allows recovery of a portion of R&D expenditure without requiring shareholder dilution, preserving capital for growth initiatives.
R&D activities driving the refund
The R&D Tax Incentive Refund relates to three core development areas:
- Proprietary biomaterial and medical device programmes focused on peripheral nerve repair and related surgical applications
- Novel biomaterials and processes designed to improve surgical handling during complex nerve and tissue repair procedures
- Projects aimed at reducing post-surgical complications, including scarring and infection, whilst supporting improved functional outcomes for patients
The refund validates ReNerve’s continued investment in differentiated technology that addresses unmet clinical needs in peripheral nerve injury repair.
Where ReNerve stands in its commercialisation journey
ReNerve’s flagship product, the FDA-cleared NervAlign® Nerve Cuff, is already generating commercial traction in the United States market. The company achieved 53% revenue growth in FY25, reaching $271k in sales. Alongside its established Empliq™ tissue product ranges, ReNerve is advancing a pipeline of next-generation nerve repair solutions.
| Status | Product |
|---|---|
| On market | NervAlign® Nerve Cuff |
| On market | Empliq™ Deep Dermal tissue product |
| On market | Empliq™ Amniotic tissue product ranges |
| In development | NervAlign® Nerve Conduit Range |
| In development | NervAlign® Nerve Guide Matrix |
| In development | NervAlign® Bionic Nerve |
What’s next for ReNerve
The $517,133 refund will primarily fund ongoing product development and support ReNerve’s commercialisation roadmap as the company pursues broader market penetration. ReNerve operates in the global nerve repair market, which was valued at US$1.6 billion in 2024 and is projected to reach US$6.2 billion by 2031. The non-dilutive capital extends the company’s operational runway whilst advancing its pipeline of nerve repair technologies toward regulatory milestones and market entry.
Want the Next Biotech Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with expert analysis. Click the “Free Alerts” button at Big News Blast to get market-moving announcements delivered straight to your inbox the moment they drop.